Sustained MYB activity is necessary for oncogenic transcription in KMT2A-rearranged acute lymphoblastic leukemia through enhancer-promoter interactions and epigenetic modifications at enhancers

Sustained MYB activity is necessary for oncogenic transcription in KMT2A-rearranged acute lymphoblastic leukemia through enhancer-promoter interactions and epigenetic modifications at enhancers

Bibliographic Details
Main Authors:	Lau, I-J, Harman, JR, Jackson, NE, Denny, N, Smith, AL, Vyas, P, Davies, JO, Hughes, J, Crump, N, Milne, TA
Format:	Conference item
Language:	English
Published:	American Society of Hematology 2023

Similar Items

Modelling acquired resistance to DOT1L inhibition exhibits the adaptive potential of KMT2A-rearranged acute lymphoblastic leukemia
by: Schneider, P, et al.
Published: (2023)

Acute Lymphoblastic Leukemia at Birth with KMT2A Gene Rearrangement
by: Sanjeev Kumar Jha, et al.

Preclinical Evaluation of Carfilzomib for Infant KMT2A-Rearranged Acute Lymphoblastic Leukemia
by: Laurence C. Cheung, et al.
Published: (2021-04-01)

Modelling acquired resistance to DOT1L inhibition exhibits the adaptive potential of KMT2A-rearranged acute lymphoblastic leukemia
by: Pauline Schneider, et al.
Published: (2023-09-01)

Updates in <i>KMT2A</i> Gene Rearrangement in Pediatric Acute Lymphoblastic Leukemia
by: Mateusz Górecki, et al.
Published: (2023-03-01)

XRCC4 rs28360071 intronic variant is associated with increased risk for infant acute lymphoblastic leukemia with KMT2A rearrangements
by: Orlando Louzada-Neto, et al.
Published: (2020-12-01)

Poor treatment responses were related to poor outcomes in pediatric B cell acute lymphoblastic leukemia with KMT2A rearrangements
by: Jinquan Wen, et al.
Published: (2022-08-01)

Acute lymphoblastic leukemia (ALL) with KMT2A gene rearrangement in infants - characteristic clinical picture based on a case report
by: Maria Kowalczuk, et al.
Published: (2022-03-01)

De novo activating mutations drive clonal evolution and enhance clonal fitness in KMT2A-rearranged leukemia
by: Axel Hyrenius-Wittsten, et al.
Published: (2018-05-01)

Synthetic oleanane triterpenoids suppress MYB oncogene activity and sensitize T-cell acute lymphoblastic leukemia cells to chemotherapy
by: Paloma Tejera Nevado, et al.
Published: (2023-04-01)

CRISPR-Cas9 Library Screening Identifies Novel Molecular Vulnerabilities in <i>KMT2A</i>-Rearranged Acute Lymphoblastic Leukemia
by: Pauline Schneider, et al.
Published: (2023-08-01)

Effective tumor cell abrogation via Venetoclax-mediated BCL-2 inhibition in KMT2A-rearranged acute B-lymphoblastic leukemia
by: Anna Richter, et al.
Published: (2022-07-01)

Genetic and Epigenetic Characterization of a Discordant <em>KMT2A/AFF1</em>-Rearranged Infant Monozygotic Twin Pair
by: Alessia Russo, et al.
Published: (2021-09-01)

PB1799: KMT2A-REARRANGED PEDIATRIC ACUTE MYELOID LEUKEMIA
by: E. Zerkalenkova, et al.
Published: (2022-06-01)

Novel Diagnostic and Therapeutic Options for KMT2A-Rearranged Acute Leukemias
by: Bruno A. Lopes, et al.
Published: (2022-06-01)

Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements
by: Ghayas C. Issa, et al.
Published: (2021-09-01)

Dysregulated transcriptional networks in KMT2A- and MLLT10-rearranged T-ALL
by: Huining Kang, et al.
Published: (2018-08-01)

Case Report: Rare <i>IKZF1</i> Gene Fusions Identified in Neonate with Congenital <i>KMT2A</i>-Rearranged Acute Lymphoblastic Leukemia
by: Laura N. Eadie, et al.
Published: (2023-01-01)

NG2 MOLECULE EXPRESSION IN ACUTE LYMPHOBLASTIC LEUKEMIA B CELLS: A FLOW-CYTOMETRIC MARKER FOR THE RAPID IDENTIFICATION OF KMT2A GENE REARRANGEMENTS
by: Maria Laura Bisegna, et al.
Published: (2024-02-01)

Combined BCL-2 and PI3K/AKT Pathway Inhibition in <i>KMT2A</i>-Rearranged Acute B-Lymphoblastic Leukemia Cells
by: Clemens Holz, et al.
Published: (2023-01-01)

Drug Repurposing for Targeting Acute Leukemia With KMT2A (MLL)—Gene Rearrangements
by: Alexia Tsakaneli, et al.
Published: (2021-09-01)

Regulation of IL-20 Expression by Estradiol through KMT2B-Mediated Epigenetic Modification.
by: Chia-Hsin Su, et al.
Published: (2016-01-01)

Potent, p53-independent induction of NOXA sensitizes MLL-rearranged B-cell acute lymphoblastic leukemia cells to venetoclax
by: Fidyt, K, et al.
Published: (2022)

Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemia
by: Jennifer L. Kamens, et al.
Published: (2023-02-01)

Palbociclib in Acute Leukemias With KMT2A-rearrangement: Results of AMLSG 23-14 Trial
by: Verena I. Gaidzik, et al.
Published: (2023-05-01)

Impact of KMT2A Rearrangement and CSPG4 Expression in Pediatric Acute Myeloid Leukemia
by: Lina Marie Hoffmeister, et al.
Published: (2021-09-01)

Monocytic and blastic plasmacytoid dendritic cell differentiation in acute leukemia with KMT2A rearrangement
by: Owen Xue, et al.
Published: (2023-08-01)

Dysregulation of the DNA Damage Response and KMT2A Rearrangement in Fetal Liver Hematopoietic Cells.
by: Mai Nanya, et al.
Published: (2015-01-01)

A KMT2A-AFF1 gene regulatory network highlights the role of core transcription factors and reveals the regulatory logic of key downstream target genes
by: Harman, JR, et al.
Published: (2021)

IGH Rearrangement Evolution in Adult KMT2A-rearranged B-cell Precursor ALL: Implications for Cell-of-origin and MRD Monitoring
by: Franziska Darzentas, et al.
Published: (2023-01-01)

Pterostilbene Changes Epigenetic Marks at Enhancer Regions of Oncogenes in Breast Cancer Cells
by: Sadaf Harandi-Zadeh, et al.
Published: (2021-07-01)

Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia
by: Nuria Tubío-Santamaría, et al.
Published: (2023-12-01)

Lineage switch in relapse of acute leukemia with rearrangement of MLL gene (KMT2A). literature review and case reports
by: E. A. Zerkalenkova, et al.
Published: (2016-08-01)

INFANT EXTRAMEDULLARY KMT2A REARRANGED T/MYELOID ACUTE LEUKEMIA MIMICKING LANGERHANS CELL HISTIOCYTOSIS
by: Barbora Vakrmanova, et al.
Published: (2023-12-01)

P435: NOVEL COMPOUNDS TO TARGET KMT2A-REARRANGED PEDIATRIC ACUTE MYELOID LEUKEMIA
by: Claudia Tregnago, et al.
Published: (2023-08-01)

Novel Compounds Synergize With Venetoclax to Target KMT2A-Rearranged Pediatric Acute Myeloid Leukemia
by: Claudia Tregnago, et al.
Published: (2022-01-01)

TRANSCRIPTOME ANALYSES REVEAL NEW MARKERS FOR THE DIAGNOSIS AND TREATMENT OF KMT2A (MLL)-REARRANGED LEUKEMIA
by: BA Lopes, et al.
Published: (2021-10-01)

First case of B ALL with KMT2A-MAML2 rearrangement: a case report
by: Estelle Menu, et al.
Published: (2017-05-01)

Epigenetic Deregulation of the Histone Methyltransferase KMT5B Contributes to Malignant Transformation in Glioblastoma
by: Virginia López, et al.
Published: (2021-08-01)

Author Correction: Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemia
by: Jennifer L. Kamens, et al.
Published: (2023-03-01)